Cargando…

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

BACKGROUND: Adjuvant endocrine therapy beyond 5 years reduces recurrence in patients with estrogen receptor–positive breast cancer. We have previously shown that immunohistochemical markers (IHC4) and two gene expression profile tests (recurrence score [RS] and PAM50 risk of recurrence [ROR]) are as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestak, Ivana, Dowsett, Mitch, Zabaglo, Lila, Lopez-Knowles, Elena, Ferree, Sean, Cowens, J. Wayne, Cuzick, Jack
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787911/ https://www.ncbi.nlm.nih.gov/pubmed/24029245 http://dx.doi.org/10.1093/jnci/djt244

Ejemplares similares

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Sestak, Ivana, et al.
Publicado: (2018)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Who would have thought a single Ki67 measurement would predict long-term outcome?
por: Dowsett, Mitch, et al.
Publicado: (2009)

Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations
por: Dowling, Ryan J O, et al.
Publicado: (2019)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions
por: Dowling, Ryan J O, et al.
Publicado: (2019)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer
por: Gao, Qiong, et al.
Publicado: (2018)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
por: Simigdala, Nikiana, et al.
Publicado: (2016)

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
por: Yeo, B, et al.
Publicado: (2015)

The Difference in Prognostic Factors between Early Recurrence and Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Nodal Stage Differently Impacts Early and Late Recurrence
por: Ahn, Sung Gwe, et al.
Publicado: (2013)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2020)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
por: Cuzick, Jack, et al.
Publicado: (2013)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor‐positive breast cancer
por: Fukuoka, Megumi, et al.
Publicado: (2022)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
por: Ellis, Matthew J., et al.
Publicado: (2008)

The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
por: Tajiri, Wakako, et al.
Publicado: (2020)

Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients
por: Han, Hyun Ho, et al.
Publicado: (2016)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

SNPs for breast cancer risk assessment
por: Cuzick, Jack, et al.
Publicado: (2017)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
por: Kumeta, Toko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r1o11n4flm41btjkmbe5n209f2